Background: To report the ocular manifestations of neuro-Behcet's disease.
Cases: A 34-year-old woman had recurrent meningitis. She developed diplopia, headache, and ataxia, and was diagnosed as having neuro-Behcet's disease.
Observations: Imaging revealed two infarct foci in the transitional midbrain and pons. After treatment with prednisolone and colchicine, the diplopia resolved. Two years later, a scotoma developed in the right eye, in which the best-corrected visual acuity was 4/200. Papillitis and a prepapillary vitreous opacity were seen in the right fundus. These findings disappeared 11 days after subconjunctival steroid injections and increased colchicine. Her vision gradually improved to 20/20 two months later.
Conclusion: Neuro-Behcet's disease may manifest with transient optic neuritis and prepapillary vitreous opacity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0021-5155(01)00466-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neuro-Behçet's disease: an update of clinical diagnosis, biomarkers and immunopathogenesis.
Clin Exp Immunol
January 2025
Department of Clinical Laboratory, State key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Neuro-Behçet's disease (NBD) is a more severe but rare symptom of Behçet's disease (BD), which is mainly divided into parenchymal NBD (p-NBD) involving brain stem, spinal cord, and cerebral cortex. Non-p-NBD manifests as intracranial aneurysm, cerebral venous thrombosis, peripheral nervous system injuries, and mixed parenchymal and non-parenchymal disease. P-NBD is pathologically characterized by perivasculitis presenting with cerebrospinal fluid (CSF) pleocytosis, elevated total protein, and central nervous system (CNS) infiltration of macrophages and neutrophils, which are subdivided into acute and chronic progressive stages according to relapsing-remitting courses and responses to steroids.
View Article and Find Full Text PDF[Analysis of the clinical features and prognosis of neuro-Behcet's syndrome in 5 children].
Zhonghua Er Ke Za Zhi
January 2025
Department of Rheumatology and Immunology, Children's Hospital Affiliated to Capital Institute of Pediatrics, Beijing100020, China.
Article Synopsis
- The study examined the clinical features and prognosis of neuro-Behçet's syndrome (NBS) in 5 children, analyzing their medical data over a span of 10 years from various pediatric departments.
- The patients, aged between 8 to 17 years, exhibited variable symptoms like headaches, convulsions, and impaired motor functions; some showed no symptoms, highlighting the non-specific nature of NBS.
- Treatment involved corticosteroids alongside immunosuppressants, resulting in positive outcomes for most patients, although one individual discontinued treatment; imaging showed diverse brain lesions not easily identifiable as NBS.
Neuro-Behçet's Disease Masquerading as Multiple Sclerosis in a Young Male.
Clin Case Rep
December 2024
Multiple Sclerosis Research Center, Neuroscience Institute Tehran University of Medical Sciences Tehran Iran.
This case highlights the importance of considering Neuro-Behçet's disease (NBD) in the differential diagnosis of multiple sclerosis (MS), particularly in patients presenting with neurological manifestations, abnormal magnetic resonance imaging (MRI) findings, and systemic symptoms consistent with Behçet's disease (BD).
View Article and Find Full Text PDFNeuro-Behçet leading to coma: A case report.
Radiol Case Rep
January 2025
Central Radiology Department, Ibn Sina University Hospital Center, Mohamed V University of Rabat, Rabat, Morocco.
Neuro-Behçet disease is often difficult to diagnose due to its complex and severe clinical presentation. This article reports the case of a 35-year-old female patient with a history of Behçet's disease, admitted for a deep coma. Brain MRI performed upon admission revealed extended lesions in the basal ganglia, thalami, and midbrain, along with leptomeningeal contrast enhancement in the temporal region, suggesting meningoencephalitis compatible with parenchymal involvement of neuro-Behçet's disease.
View Article and Find Full Text PDFInfliximab versus Cyclophosphamide for Severe Behçet's Syndrome.
NEJM Evid
November 2024
Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Centre national de références Maladies Autoimmunes et systémiques rares, National Reference Centre for Rare Autoinflammatory Diseases and Inflammatory Amyloidosis, INSERM, UMR S959, Immunology-Immunopathology-Immunotherapy, Paris.
Article Synopsis
- A study compared the effectiveness and safety of infliximab and cyclophosphamide as induction therapies for severe Behçet's syndrome involving major vascular or CNS issues.
- Infliximab showed a higher complete response rate (81%) compared to cyclophosphamide (56%), indicating it may be more effective.
- Additionally, infliximab had fewer adverse events (29.6%) compared to cyclophosphamide (64%), suggesting it may also be safer for patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!